摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(+/-)-α-narcotine; hydrochloride | 912-60-7

中文名称
——
中文别名
——
英文名称
(+/-)-α-narcotine; hydrochloride
英文别名
(+/-)-α-Narcotin; Hydrochlorid;6,7-dimethoxy-3-(4-methoxy-6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-2-benzofuran-1(3H)-one hydrochloride;(3R)-6,7-dimethoxy-3-[(5S)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one;hydrochloride
(+/-)-α-narcotine; hydrochloride化学式
CAS
912-60-7;6057-45-0;115881-06-6
化学式
C22H23NO7*ClH
mdl
——
分子量
449.888
InChiKey
MFLVZFXCSKVCSH-CJRXIRLBSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    221-223 °C(lit.)
  • 溶解度:
    易溶于水和乙醇(96%)。水溶液呈微酸性;当溶液静置时,遇碱可能会沉淀。

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    31
  • 可旋转键数:
    4
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.41
  • 拓扑面积:
    75.7
  • 氢给体数:
    1
  • 氢受体数:
    8

安全信息

  • 危险等级:
    6.1(b)
  • 危险品标志:
    Xi
  • 安全说明:
    S36
  • 危险类别码:
    R22
  • WGK Germany:
    3
  • 危险品运输编号:
    UN 1544
  • RTECS号:
    NP7225000
  • 包装等级:
    III
  • 危险类别:
    6.1(b)

SDS

SDS:d50f5093f26f55d27bf832206dba02b5
查看

制备方法与用途

那可丁系支气管解痉性镇咳药物,效应如阿片,能解除支气管平滑肌痉挛,从而缓解阵发性咳嗽,具有与可待因大致相等的镇咳作用,无成瘾性和镇痛及中枢抑制的药理活性。据报本品有一定呼吸中枢兴奋功效。那可丁是罂粟属阿片的邻苯二甲酸异喹啉生物碱,药用品为那可丁盐酸盐(商品名:乐咳平,诺司咳平)。本品用途类似于右美沙芬,也有罂粟碱样支气管平滑肌解痉作用,能抑制咳嗽中枢和肺牵张反射引起的咳嗽,其镇咳作用与可待因相当,特点是无镇痛、镇静作用,无欣快感,无成瘾性和耐受性,不抑制呼吸和肠蠕动,相反,还有一定的呼吸中枢兴奋作用,服用后药效可持续4h,临床上主要用于刺激性干咳患者。那可丁在过去几十年中一直被用作镇咳药,口服给药,1h后达血浆最大浓度,半衰期为124min,绝对口服利用度为30%,主要代谢物包括cotarnine、hydrocotarnine和meconin,均来自于异喹啉和2-苯并呋喃酮环之间C-C键的断裂,其代谢物的归属、生物利用度和药动学都已得到了较深入的研究临床主要用于支气管哮喘病人的干咳及各种原因引起的阵发性咳嗽。Noscapine hydrochloride ((S,R)-Noscapine hydrochloride) 是一种具有口服活性的苯酞异喹啉生物碱,具有强效镇咳作用。Noscapine hydrochloride 通过激活 sigma 阿片类受体 (sigma opioid receptors) 发挥镇咳作用,是一种非竞争性 Bradykinin 抑制剂。Noscapine hydrochloride 破坏微管动力学,诱导细胞有丝分裂停滞和凋亡 (apoptosis) 以及活性。Noscapine hydrochloride 具有抗癌,神经保护,抗炎活性,并且可以穿越血脑屏障。

Sigma opioid receptors Bradykinin Apoptosis

Noscapine (0-1000 μM; 0-96 hours; rat C6 glioma cells) treatment inhibits cell viability of rat C6 glioma in vitro in a dose- and time-dependent manner. Noscapine inhibits the viability of rat C6 glioma cells with an IC 50 of 250 μM at 72 hours.
Noscapine exposure causes abnormal S-phase reentry, increases mitotic arrest and results in excessive DNA accumulation.
Cylindromatosis increases the ability of noscapine to induce mitotic arrest and apoptosis. Cylindromatosis enhances the effect of noscapine on microtubule polymerization and promotes noscapine binding to microtubules.

Cell Proliferation Assay

Cell Line: Rat C6 glioma cells
Concentration: 0 μM, 0.1 μM, 1 μM, 2 μM, 10 μM, 50 μM, 100 μM, 1000 μM
Incubation Time: 0 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours
Result: Inhibited cell viability of rat C6 glioma in vitro in a dose- and time-dependent manner.

Noscapine (300 mg/kg; oral gavage; daily; for 15 days; athymic female mice) treatment reduces tumor growth in mice.

Animal Model: Athymic female mice (nu/nu) (8-week-old) injected with rat C6 glioma cells
Dosage: 300 mg/kg
Administration: Oral gavage; daily; for 15 days
Result: Revealed a significant reduction of tumor volume.

同类化合物

阿托喹啉 那可汀 那可丁N-氧化物 诺司卡品 盐酸盐 水合物 细果角茴香碱 紫堇明 盐酸那可丁一水合物 盐酸诺格考平 盐酸白毛莨碱 曲托喹啉 山缘草定碱 咖喏定 北美黄连碱 [S-(R*,R*)]-6,7-二甲氧基-3-(5,6,7,8-四氢-4-羟基-6-甲基-1,3-二氧杂环戊并[4,5-g]异喹啉-5-基)苯酞 [6S,(+)]-6-[(1S)-1,2,3,4-四氢-6,7-二甲氧基-2-甲基异喹啉-1-基]呋喃并[3,4-e]-1,3-苯并二氧戊环-8(6H)-酮 7-氨基-4,5,6-三乙氧基-3-(6,7,8-三甲氧基-2-甲基-3,4-二氢-1H-异喹啉-1-基)-3H-2-苯并呋喃-1-酮 7-O-去甲基alpha-那可丁 6,7-二甲氧基-3-[(5R)-4-甲氧基-6-甲基-7,8-二氢-5H-[1,3]二氧杂环戊并[4,5-g]异喹啉-5-基]-3H-2-苯并呋喃-1-酮 3-异喹啉-1-基-3H-2-苯并呋喃-1-酮 (3S)-6,7-二甲氧基-3-[(5S)-6-甲基-5,6,7,8-四氢[1,3]二氧杂环戊并[4,5-g]异喹啉-5-基]-2-苯并呋喃-1(3H)-酮 (3S)-3-[(1R)-6,7-二羟基-8-甲氧基-2-甲基-3,4-二氢-1H-异喹啉-1-基]-6,7-二甲氧基-3H-2-苯并呋喃-1-酮 (-)-荷苞牡丹碱甲溴化物 (-)-荷苞牡丹碱 (-)-荷包牡丹碱甲碘化物 (-)-荷包牡丹碱甲溴化物 (-)-荷包牡丹碱甲氯化物 (-)-紫堇明 (+)-荷苞牡丹碱甲氯化物 (+)-荷包牡丹碱 8-Isopentyl-narcotolin 8-<4-Chlor-benzyl>-narcotolin (R)-5-((R)-4,5-dimethoxy-3-oxo-phthalan-1-yl)-4-methoxy-6,6-dimethyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolinium; iodide 8-Allylnarkotolin 8-p-Nitrobenzylnarkotolin 2-(thiazolidin-3-yl)ethyl (E)-6-[1,3-dihydro-4-(N-(trifluoroacetyl)-N-isopropyl)amino-6-methoxy-7-methyl-3-oxoisobenzofuran-5-yl]-4-methyl-4-hexenoate 2-[5-(4,5-Dimethoxy-3-oxo-1,3-dihydro-isobenzofuran-1-yl)-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-4-yloxy]-N-(4-ethoxy-phenyl)-acetamide 8-Narcotolinessigsaeureethylester 2-[5-(4,5-Dimethoxy-3-oxo-1,3-dihydro-isobenzofuran-1-yl)-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-4-yloxy]-N-(4-sulfamoyl-phenyl)-acetamide 6-(6',7'-diacetoxy-2'-methyl-1',2',3',4'-tetrahydroisoquinolin-1'-yl)furo<3,4-e>-1,3-benzodioxol-8(6H)-one hydrobromide 6,7-dimethoxy-3(7-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)isobenzofuran-1(3H)-one 5-((R)-4,5-Dimethoxy-3-oxo-1,3-dihydro-isobenzofuran-1-yl)-6-methyl-7,8-dihydro-[1,3]dioxolo[4,5-g]isoquinolin-6-ium (+/-)-erythro-1-<1'-(4',5'-dimethoxyphthalidyl)>-2-methyl-1,2,3,4-tetrahydroisoquinoline 6-(6',7'-dihydroxy-2'-methyl-1',2',3',4'-tetrahydroisoquinolin-1'-yl)furo<3,4-e>-1,3-benzodioxol-8(6H)-one hydrobromide 4-{2-[5-(4,5-Dimethoxy-3-oxo-1,3-dihydro-isobenzofuran-1-yl)-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-4-yloxy]-acetylamino}-benzoic acid ethyl ester Corledin-acetat (-)-α-hydrastine; hydrochloride N-Aminonarcotiniumion 3d-β-Narcotin rac-2,3;10,11-bis-methanediyldioxy-16ξ-methyl-16ξ-oxy-rheadan-8-one (1R,5R)-8,9,18,19-tetramethoxy-3-oxa-13-azapentacyclo[11.8.0.01,5.06,11.016,21]henicosa-6,8,10,16,18,20-hexaene-4,12-dione